BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Inimex Pharmaceuticals Inc. Selected As One Of Canada's Top 10 Life Science Investment Prospects


11/8/2005 11:03:49 AM

VANCOUVER, Nov. 8 /PRNewswire/ - Inimex Pharmaceuticals, Inc. is pleased to announce that it has been selected as one of the Top 10 Investment Prospects in Canada's Top 10 Life Science Companies Competition (Canada's Top 10) for the fourth year in a row. According to competition sponsor Ken Lawless, President and CEO of the Ottawa Life Sciences Council, "In recent years, Canada's Top 10 have consistently proven to be a highly accurate indicator of the likely success stories in Canada's life sciences sector."

Inimex was selected from a pool of entrants by an independent international jury of Canadian and U.S. life science venture capitalists commissioned by the Ottawa Life Sciences Council. Selected companies are divided into two categories: early stage companies (seeking first and second round financing) or emerging and later stage opportunities (seeking mezzanine or later stage financing). A winner in three previous Early Stage Companies competitions, Inimex this year was selected as one of five companies in the Emerging and Later Stage Companies category.

"It is gratifying to be recognized as one of Canada's leading biotechnology investment opportunities by a distinguished panel of venture capitalists," stated Dr. John R. North, President & CEO, Inimex Pharmaceuticals. "Inimex technology represents the 'next wave' of innate immunity drugs - Inimex drugs fill the gap between vaccines and antibiotics due to their rapid action and broad spectrum activity, which is uncomplicated by drug resistance. Inimex is preparing to hold pre-IND discussions with the FDA to initiate our first formal preclinical program. We are pleased the jury recognized the broad commercial potential of our technology platform and the significant opportunity we have to develop new medicines for infectious diseases and inflammation based on the enhancement of innate immunity."

As recognition for the award, Dr. North will present Inimex technology to investors at the upcoming BioNorth 2005 Conference, to be held November 28-29, 2005 at the Ottawa Congress Center in Ottawa, Canada. North's presentation will include details of Inimex' recent selection of an optimized proprietary compound, IMX942, for clinical development as a novel therapy for infections associated with fever and neutropenia in cancer patients undergoing chemotherapy.

Inimex is actively pursuing discussions with investors to raise up to US$ 20M in private equity capital. These funds will advance the Company's lead neutropenia program into clinical development and an inflammatory disease program into formal preclinical evaluation.

About Inimex Pharmaceuticals, Inc.

----------------------------------

Inimex Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of new medicines based on the selective modulation of the innate immune response. Inimex' first in class products show promise for the safe and effective treatment of a broad spectrum of serious unmet medical needs in infectious disease, cancer, and inflammatory disease. In 2004 the Company announced a US$ 6.8M Series A venture financing with leading Canadian investors, including the Business Development Bank of Canada, the Working Opportunity Fund (EVCC) Ltd., managed by GrowthWorks Capital, the Canadian Medical Discoveries Fund, Inc. and BC Medical Innovations Fund, Inc., advised by MDS Capital, Inc., BC Advantage Funds (EVCC) Ltd. and British Columbia Discovery Fund (VCC), Inc.

For further information, please visit the company website, www.inimexpharma.com or contact:

Roger Graham, Ph.D. Vice President, Corporate Development Inimex Pharmaceuticals, Inc. Tel.: 604-225-2251 Fax: 604-225-2257 rgraham@inimexpharma.com

Inimex Pharmaceuticals Inc.

CONTACT: please visit the company website, www.inimexpharma.com orcontact: Roger Graham, Ph.D., Vice President, Corporate Development, InimexPharmaceuticals, Inc., Tel.: (604) 225-2251, Fax: (604) 225-2257,rgraham@inimexpharma.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES